Drug intelligence / Profile preview

muJ591

Development stage: Phase 1
Lead developer: Weill Cornell Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

muJ591 is a murine monoclonal antibody that recognizes the extracellular domain of prostate-specific membrane antigen (PSMA). PSMA is highly expressed by malignant prostate epithelial cells and vascular endothelial cells of numerous solid tumor malignancies. The antibody has been used in various radiolabeled forms for targeted therapy and imaging of prostate cancer.

Other names: murine J591mouse J591

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on muJ591.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on muJ591.

Explore the full profile